RxDoctor Payments Data

Steven Factor, MD

Neurology · Abington, PANPI 1730472408

Payments from drug & device makers

$130,177in general payments, 2019–2025

Across 731 payments — averaging $178.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$119K
  • Pfizer$2K
  • Teva Pharmaceuticals USA, Inc.$962
  • Amgen$795
  • AstraZeneca$653
  • Lilly USA, LLC$575
  • plus $5K from 54 others

What the payments were for

  • Consulting fees$2,2503%
  • Speaking & faculty fees$52,69478%
  • Travel & lodging$210%
  • Food & beverage$12,75819%
  • Education$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)229$119,331
Pfizer41$2,447
Teva Pharmaceuticals USA, Inc.51$962
Amgen53$795
AstraZeneca(2 entities)31$653
Lilly USA, LLC30$575
Argenx US, Inc.17$458
Upsher-smith Laboratories LLC22$423
UCB, Inc.16$290
Supernus Pharmaceuticals, Inc.20$286
Lundbeck LLC13$252
CSL Behring9$209
Biohaven Pharmaceuticals, Inc.19$191
Biohaven Pharmaceutical Holding Company Ltd.11$179
Impel Pharmaceuticals Inc.20$179
Jazz Pharmaceuticals Inc.8$169
Sunovion Pharmaceuticals Inc.8$167
Ipsen Biopharmaceuticals, Inc8$165
Amneal Pharmaceuticals LLC8$143
Sumitomo Pharma America, Inc.9$138
Johnson & Johnson(2 entities)6$123
Novartis6$120
SK Life Science, Inc.7$118
DIXI Medical USA Corp1$97
EMD Serono, Inc.5$95
Eisai Inc.5$95
Merz Pharmaceuticals, LLC5$91
Akcea Therapeutics, Inc.1$91
Kyowa Kirin, Inc.5$89
Otsuka America Pharmaceutical, Inc.4$77
Mallinckrodt Enterprises LLC3$72
Harmony Biosciences LLC4$71
Biogen4$66
Axsome Therapeutics, Inc.3$59
Aucta Pharmaceuticals, Inc.2$56
Neurelis, Inc.3$53
Boston Scientific3$52
Scilex Pharmaceuticals Inc.3$52
Tersera Therapeutics LLC3$51
Arbor Pharmaceuticals, Inc.3$46
Sanofi2$46
MDD US Operations, LLC2$45
Genentech USA, Inc.2$40
Grifols USA, LLC2$39
Acorda Therapeutics, Inc2$38
Assertio Therapeutics, Inc.2$36
Promius Pharma LLC2$33
Tanabe Pharma America, Inc.2$31
Springworks Therapeutics, Inc.1$30
Greenwich Biosciences, Inc.2$30
Avion Pharmaceuticals2$30
Hoffmann-la Roche Limited1$25
Abbott1$24
Impel Pharmaceuticals LLC1$21
Almatica Pharma LLC1$19
Adamas Pharmaceuticals, Inc.1$18
Avanir Pharmaceuticals, Inc.1$17
Aquestive Therapeutics, Inc.1$16
GE HealthCare1$15
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,177 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$262,757
Medicare patients
531
Services billed
17,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate31$63,841
Aimovig AutoinjectorErenumab-Aooe20$26,130
QuliptaAtogepant13$14,080
Emgality PenGalcanezumab-Gnlm11$7,197
Lacosamide11$2,135
Carbidopa-LevodopaCarbidopa/Levodopa59$1,236
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine18$1,235
Topiramate20$821
Zonisamide25$653
Gabapentin55$572
Sumatriptan Succinate37$480
Levetiracetam25$478
RizatriptanRizatriptan Benzoate21$250
Pregabalin19$207
Duloxetine Hcl11$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$2,447$63,84131 claims
AbbVieQulipta$119,331$14,08013 claims
Upsher-smith Laboratories LLCTopiramate$423$82120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →